Prelude Capital Management, LLC Sorrento Therapeutics, Inc. Call Options Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2021

Aug 16, 2021
SELL
$6.35 - $10.0 $73,660 - $116,000
-11,600 Closed
0 $0
Q1 2021

May 17, 2021
BUY
$7.03 - $16.51 $9,139 - $21,463
1,300 Added 12.62%
11,600 $96,000
Q4 2020

Feb 16, 2021
SELL
$5.76 - $11.95 $167,616 - $347,745
-29,100 Reduced 73.86%
10,300 $70,000
Q3 2020

Nov 16, 2020
SELL
$6.17 - $18.82 $35,169 - $107,274
-5,700 Reduced 12.64%
39,400 $439,000
Q2 2020

Aug 14, 2020
BUY
$1.73 - $6.76 $33,043 - $129,116
19,100 Added 73.46%
45,100 $283,000
Q1 2020

May 15, 2020
BUY
$1.57 - $4.76 $40,820 - $123,760
26,000 New
26,000 $48,000

Others Institutions Holding SRNE

# of Institutions
12
Shares Held
5.47M
Call Options Held
0
Put Options Held
0
View Full List

About Sorrento Therapeutics, Inc.

SRNE Quotes by TradingView
  • Ticker SRNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 449,952,000
  • Market Cap $148M
  • Description
  • Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...
More about SRNE
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email